Clinical Trial Update: A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants [Phase 2]

View source ↗

Summary

Phase 2 study of sabatolimab in combination with azacitidine and venetoclax in high- or very high-risk myelodysplastic syndrome was terminated; results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Sabatolimab (sabatolimab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndrome (MDS) | Phase 2 | Status: TERMINATED | Results posted: 2024-06-11